全文获取类型
收费全文 | 17712篇 |
免费 | 2575篇 |
国内免费 | 575篇 |
出版年
2024年 | 37篇 |
2023年 | 614篇 |
2022年 | 519篇 |
2021年 | 1409篇 |
2020年 | 1408篇 |
2019年 | 1972篇 |
2018年 | 1294篇 |
2017年 | 873篇 |
2016年 | 785篇 |
2015年 | 1000篇 |
2014年 | 1582篇 |
2013年 | 1857篇 |
2012年 | 846篇 |
2011年 | 984篇 |
2010年 | 544篇 |
2009年 | 625篇 |
2008年 | 564篇 |
2007年 | 609篇 |
2006年 | 570篇 |
2005年 | 451篇 |
2004年 | 369篇 |
2003年 | 334篇 |
2002年 | 277篇 |
2001年 | 158篇 |
2000年 | 142篇 |
1999年 | 119篇 |
1998年 | 125篇 |
1997年 | 96篇 |
1996年 | 79篇 |
1995年 | 88篇 |
1994年 | 73篇 |
1993年 | 68篇 |
1992年 | 68篇 |
1991年 | 56篇 |
1990年 | 31篇 |
1989年 | 32篇 |
1988年 | 33篇 |
1987年 | 27篇 |
1986年 | 14篇 |
1985年 | 25篇 |
1984年 | 23篇 |
1983年 | 6篇 |
1982年 | 13篇 |
1981年 | 9篇 |
1980年 | 8篇 |
1979年 | 13篇 |
1978年 | 8篇 |
1977年 | 4篇 |
1976年 | 4篇 |
1974年 | 4篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer
Elizabeth A. Bowling Jarey H. Wang Fade Gong William Wu Nicholas J. Neill Ik Sun Kim Siddhartha Tyagi Mayra Orellana Sarah J. Kurley Rocio Dominguez-Vidaña Hsiang-Ching Chung Tiffany Y.-T. Hsu Julien Dubrulle Alexander B. Saltzman Heyuan Li Jitendra K. Meena Gino M. Canlas Srinivas Chamakuri Thomas F. Westbrook 《Cell》2021,184(2):384-403.e21
42.
43.
44.
Cvek Jakub Vondráček Vladimir Dvořák Jan Argalacsová Sona Navrátil Matej Buřil Jan 《Reports of Practical Oncology and Radiotherapy》2012,17(2):79-84
AimTo evaluate the outcome of prostate cancer patients with initial PSA value >40 ng/ml.BackgroundThe outcome of prostate cancer patients with very high initial PSA value is not known and patients are frequently treated with palliative intent. We analyzed the outcome of radical combined hormonal treatment and radiotherapy in prostate cancer patients with initial PSA value >40 ng/ml.MethodsBetween January 2003 and December 2007 we treated, with curative intent, 56 patients with non-metastatic prostate cancer and initial PSA value >40 ng/ml. The treatment consisted of two months of neoadjuvant hormonal treatment (LHRH analog), radical radiotherapy (68–78 Gy, conformal technique) and an optional two-year adjuvant hormonal treatment.ResultsThe median time of follow up was 61 months. 5-Year overall survival was 90%. 5-Year biochemical disease free survival was 62%. T stage, Gleason score, PSA value, and radiotherapy dose did not significantly influence the outcome. Late genitourinal and gastrointestinal toxicity was acceptable.ConclusionRadical treatment in combination with hormonal treatment and radiotherapy can be recommended for this subgroup of prostate cancer patients with good performance status and life expectancy. 相似文献
45.
Comment on: Rokavec M, et al. Mol Cell 2012; 45:777-89. 相似文献
46.
47.
Manuel Algara Meritxell Arenas Dolores De las Peñas Eloisa Bayo Julia Muñoz José Antonio Carceller Juan Salinas Ferran Moreno Francisco Martínez Ezequiel González Ángel Montero 《Reports of Practical Oncology and Radiotherapy》2012,17(3):122-128
AimTo evaluate the resources and techniques used in the irradiation of patients with breast cancer after lumpectomy or mastectomy and the status of implementation of new techniques and therapeutic schedules in our country.BackgroundThe demand for cancer care has increased among the Spanish population, as long as cancer treatment innovations have proliferated. Radiation therapy in breast cancer has evolved exponentially in recent years with the implementation of three-dimensional conformal radiotherapy, intensity modulated radiotherapy, image guided radiotherapy and hypofractionation.Material and MethodsAn original survey questionnaire was sent to institutions participating in the SEOR-Mama group (GEORM). In total, the standards of practice in 969 patients with breast cancer after surgery were evaluated.ResultsThe response rate was 70% (28/40 centers). In 98.5% of cases 3D conformal treatment was used. All the institutions employed CT-based planning treatment. Boost was performed in 56.4% of patients: electrons in 59.8%, photons in 23.7% and HDR brachytherapy in 8.8%. Fractionation was standard in 93.1% of patients. Supine position was the most frequent. Only 3 centers used prone position. The common organs of risk delimited were: homolateral lung (80.8%) and heart (80.8%). In 84% histograms were used. An 80.8% of the centers used isocentric technique. In 62.5% asymmetric fields were employed. CTV was delimited in 46.2%, PTV in 65% and both in 38.5%. A 65% of the centers checked with portal films. IMRT and hypofractionation were used in 1% and in 5.5% respectively.ConclusionIn most of centers, 3D conformal treatment and CT-based planning treatment were used. IMRT and hypofractionation are currently poorly implemented in Spain. 相似文献
48.
49.
Youra Kim Prathyusha Konda J. Patrick Murphy Joao A. Paulo Steven P. Gygi Shashi Gujar 《Molecular & cellular proteomics : MCP》2022,21(2):100182
The combination cancer immunotherapies with oncolytic virus (OV) and immune checkpoint blockade (ICB) reinstate otherwise dysfunctional antitumor CD8 T cell responses. One major mechanism that aids such reinstatement of antitumor CD8 T cells involves the availability of new class I major histocompatibility complex (MHC-I)-bound tumor epitopes following therapeutic intervention. Thus, therapy-induced changes within the MHC-I peptidome hold the key to understanding the clinical implications for therapy-reinstated CD8 T cell responses. Here, using mass spectrometry–based immuno-affinity methods and tumor-bearing animals treated with OV and ICB (alone or in combination), we captured the therapy-induced alterations within the tumor MHC-I peptidome, which were then tested for their CD8 T cell response-stimulating activity. We found that the oncolytic reovirus monotherapy drives up- as well as downexpression of tumor MHC-I peptides in a cancer type and oncolysis susceptibility dependent manner. Interestingly, the combination of reovirus + ICB results in higher numbers of differentially expressed MHC-I-associated peptides (DEMHCPs) relative to either monotherapies. Most importantly, OV+ICB-driven DEMHCPs contain biologically active epitopes that stimulate interferon-gamma responses in cognate CD8 T cells, which may mediate clinically desired antitumor attack and cancer immunoediting. These findings highlight that the therapy-induced changes to the MHC-I peptidome contribute toward the reinstated antitumor CD8 T cell attack established following OV + ICB combination cancer immunotherapy. 相似文献
50.
Benjamin C. Blum Weiwei Lin Matthew L. Lawton Qian Liu Julian Kwan Isabella Turcinovic Ryan Hekman Pingzhao Hu Andrew Emili 《Molecular & cellular proteomics : MCP》2022,21(1):100189
Metabolism is recognized as an important driver of cancer progression and other complex diseases, but global metabolite profiling remains a challenge. Protein expression profiling is often a poor proxy since existing pathway enrichment models provide an incomplete mapping between the proteome and metabolism. To overcome these gaps, we introduce multiomic metabolic enrichment network analysis (MOMENTA), an integrative multiomic data analysis framework for more accurately deducing metabolic pathway changes from proteomics data alone in a gene set analysis context by leveraging protein interaction networks to extend annotated metabolic models. We apply MOMENTA to proteomic data from diverse cancer cell lines and human tumors to demonstrate its utility at revealing variation in metabolic pathway activity across cancer types, which we verify using independent metabolomics measurements. The novel metabolic networks we uncover in breast cancer and other tumors are linked to clinical outcomes, underscoring the pathophysiological relevance of the findings. 相似文献